semaglutide protocol 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial Semaglutide (20mg Vial) Dosage Protocol

Bone density status in a large population of patients with anorexia nervosa

The breakthroughs come much later, often in unexpected directions

Ongoing #GLP1 -RA Trials on #ASCVD #SELECT: Semaglutide vs Placebo in Patients With Obesity and ASCVD Without DM #SOUL: Semaglutide vs Placebo in Adults With T2D With ASCVD or CKD #SURPASS-CVOT: Tirzepatide vs Dulaglutide in Patients With T2D and ASCVD #SURMOUNT-MMO: Tirzepatide vs Placebo in Adults With Obesity With or at High Risk for ASCVD Without Diabetes #CardioTwitter #GLP1RA Ongoing #GLP1 -RA Trials on #ASCVD #SELECT: Semaglutide vs Placebo in Patients With Obesity and ASCVD Without DM #SOUL: Semaglutide vs Placebo in Adults With T2D With ASCVD or CKD #SURPASS-CVOT: Tirzepatide vs Dulaglutide in Patients With T2D and ASCVD #SURMOUNT-MMO: Tirzepatide vs Placebo in Adults With Obesity With or at High Risk for ASCVD Without Diabetes #CardioTwitter #GLP1RA

This includes: Medical Assessment : Evaluation of current health status, including medical history, physical examination, and laboratory tests

EMERGING RISK SIGNALS A recent analysis published in The British Medical Journal (BMJ) Medicine has found that patients who discontinue GLP-1 therapies may face increased cardiovascular risks